Hofseth Biocare ASA Announces Exciting New Project
Hofseth BioCare ASA is embarking on an ambitious journey with a recent Board decision to initiate the construction of a second hydrolysis plant in Norway. This significant project is set to be developed through HBC Berkåk AS, a wholly owned subsidiary of the Company.
Plant Capacity Expansion and Sustainable Practices
The new plant in Berkåk aims to produce clinical-grade, sustainable marine proteins, collagens, and oils derived from Norwegian Atlantic salmon. This facility is projected to have a manufacturing capacity that is 2.5 times greater than that of the current Midsund facility, ensuring that HBC can meet the vastly increasing demand for its high-quality products.
HBC is committed to continuous innovation in research and development, which is key to improving and expanding its unique portfolio of sustainably sourced ingredients. These ingredients not only cater to the human market but are also being tailored for the pet health sector globally.
Funding and Development Plans
As part of the development process, HBC intends to secure funding for the capital expenditure and operational needs for the Berkåk facility over the next few months. This will involve exploring bank loans and leasing arrangements to support the ambitious scale-up. Ultimately, this project reflects HBC’s goal to significantly boost production volumes of its distinctive marine ingredients more than threefold.
Commitment to Sustainability and Circular Economy
Hofseth BioCare ASA is deeply dedicated to sustainability, a principle that pervades its operational processes. The Company emphasizes environmental responsibility by employing proprietary technologies to ensure there is no waste in its operations. By upcycling the fish offcuts not utilized for fillet production, HBC transforms these materials into bioactive ingredients that carry patented health benefits.
Market Demand and Innovative Products
The surge in demand for marine-based proteins is further propelled by recent studies revealing that HBC’s ProGo® Bioactive Peptides activate GLP-1, a crucial factor in metabolic health.
[Contact Information] For more details regarding HBC's innovative projects or product lines, please reach out to: Jon Olav Ødegård, CEO of HBC, at +47 936 32 966 or via email.
About Hofseth BioCare ASA
Founded on values promoting sustainability and optimal resource management, HBC positions itself as a leading supplier of health ingredients for both consumer and pet markets. They are also recognized as a platform for new drug development.
Focus Areas and Clinical Trials
The ongoing clinical trials for OmeGo® aim to enhance lung health, particularly for individuals with allergies or those in polluted urban environments. Additionally, recent results from a study involving mild COVID indicated immune health benefits, underscoring HBC's dedication to advancing health through its products.
Regarding joint health, CalGo® is under study to illustrate the advantages of type II collagen, while ProGo® is designed to enhance metabolic and gut health. Ongoing research further investigates how these ingredients impact inflammation and immune responses, positioning HBC at the forefront of health science.
Global Footprint and Accessibility
With headquarters situated in Ålesund, Norway, HBC has extended its reach to several cities worldwide, including Oslo, London, Zürich, New Jersey, and Palo Alto. Their commitment to traceability ensures that consumers can trust the origins of the marine ingredients used in their products.
Frequently Asked Questions
What is the purpose of Hofseth BioCare's new hydrolysis plant?
The new plant aims to significantly increase the production capacity of sustainably sourced marine ingredients to meet growing market demand.
How does Hofseth BioCare incorporate sustainability in its operations?
HBC utilizes innovative technology to minimize waste by upcycling fish offcuts into bioactive ingredients, aligning with sustainable practices.
What are the primary products offered by Hofseth BioCare?
HBC specializes in clinically proven marine proteins, collagens, and oils, catering to both human and pet health markets.
Who can I contact for more information about Hofseth BioCare?
For inquiries, reach out to Jon Olav Ødegård, CEO, at +47 936 32 966 or via email.
What are the recent research findings associated with HBC's products?
Recent studies indicate that HBC's ProGo® Bioactive Peptides activate GLP-1, supporting metabolic health and contributing to weight management.
